Publication | Closed Access

Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

Tuberous Sclerosis ComplexPartial EpilepsyMedicineMouse ModelsNeuropharmacologyNeurologyNeuroscienceMolecular NeurobiologyPharmacologySynaptic SignalingTuberous Sclerosis